Tag Archives: healthcare

Johnson & Johnson beats expectations despite recalls, litigation and acquisition costs

Posted on January 24, 2012 by Martin Timble

Johnson & Johnson (NYSE:JNJ) shares are trading slightly higher today after the healthcare giant posted better than expected earnings despite seeing a huge drop in profits. The company has had a year full of recalls, litigation and acquisition that seen …

Posted in Healthcare, Main Post | Tagged acquisition, analyst, earnings, healthcare, JNJ, Johnson & Johnson, litigation, NYSE, NYSE:JNJ, profits, recalls, revenue, shares, trading, Wall Street | Comments Off

What the fuss Google, Prestige Brand Holdings and Winn-Dixie?

Posted on December 20, 2011 by Josie Middleton

In this report: Prestige Brand Holdings (NYSE:PBH), Google (NASDAQ:GOOG) and Winn-Dixie Stores (NASDAQ:WINN).

Prestige Brand Holdings (NYSE:PBH) is trading over 21 percent higher today after the company announced that it would acquire 17 over the counter healthcare brands that are …

Posted in Latest Headlines, Reports | Tagged acquire, Analysts, Buy, cash, downgrade, expected, firm, GlaxoSmithKline, GOOG, Google, healthcare, investment firm, Jefferies, Kohlberg Kravis Roberts, NASDAQ, nasdaq:goog, NASDAQ:WINN, NYSE, NYSE:PBH, PBH, portfolio, Prestige Brand Holdings, products, rating, revenues, share, takeover, trading, WINN, Winn-Dixie Stores | Comments Off

PDL BioPharma drops on lower 4Q revenue forecast

Posted on December 19, 2011 by Martin Timble

PDL BioPharma (NASDAQ:PDLI) has dropped by more than 2.6 percent today after the company announced that it expects fourth quarter profits to drop by about 5 percent due to lower royalty payments for cancer drugs Avastin and Herceptin.

Both Avastin …

Posted in Healthcare, Main Post | Tagged Analysts, Avastin, company, expects, healthcare, Herceptin, markets, NASDAQ, NASDAQ:PDLI, payments, PDL BioPharma, PDLI, profit, quarter, revenue, Roche, royalty, share, trades, Wall Street | Comments Off

What the fuss Focus Media, Gilead Sciences and Ship Finance International?

Posted on November 22, 2011 by Martin Timble

In this report: Focus Media Holding (NASDAQ:FMCN), Gilead Sciences (NASDAQ:GILD) and Ship Finance International (NYSE:SFL).

Focus Media Holding (NASDAQ:FMCN) rebounded by 8 percent today after plummeting on Monday following allegations from Muddy Waters that said the company had overstated the …

Posted in Latest Headlines, Reports | Tagged acquire, advertising, allegations, audit committee, banking, BMO Capital, company, deal, drugs, financials, FMCN, Focus Media Holding, funding, GILD, Gilead Sciences, healthcare, hepatitis C, loss, Muddy Waters, NASDAQ, NASDAQ:FMCN, NASDAQ:GILD, NYSE, NYSE:SFL, Outperform, overstated, Pharmasset, rating, report, revenue, SFL, shares, Ship Finance International, uncertainties | Comments Off

What the Fuss Gilead Sciences, Clearwire and Regeneron Pharmaceuticals?

Posted on November 21, 2011 by Martin Timble

In this report: Gilead Sciences (NASDAQ:GILD), Clearwire (NASDAQ:CLWR) and Regeneron Pharmaceuticals (NASDAQ:REGN).

Gilead Sciences (NASDAQ:GILD) has dropped by over 12 percent today after it was reported that the company has agreed to be acquire Pharmasset in a deal worth around …

Posted in Latest Headlines, Reports | Tagged acquire, agreed, bankruptcy, capital, CEO, Clearwire, CLWR, company, deal, debt, delay, developmet, drug, eylea, FDA, GILD, Gilead Sciences, healthcare, investments, NASDAQ, NASDAQ:CLWR, NASDAQ:GILD, NASDAQ:REGN, payment, Pharmasset, ploy, premium, Regeneron Pharmaceuticals, REGN, report, restructure, Sprint Nextel, trading, treatment, wall street journal | Comments Off

What’s up Inhibitex, Pharmasset and Global Education & Technology?

Posted on November 21, 2011 by Martin Timble

In this report: Global Education & Technology (NASDAQ:GEDU), Pharmasset (NASDAQ:VRUS) and Inhibitex (NASDAQ:INHX).

Global Education & Technology (NASDAQ:GEDU) rallied by more than 97 percent on during early trading on Monday after it was reported that British publishing group Pearson Plc. would …

Posted in Latest Headlines, Reports | Tagged acquire, agreed, biopharmaceutical, cash, CEO, China, deal, drugs, GEDU, Gilead Sciences, Global Education & Technology, growth, healthcare, hepatitis C, Inhibitex, INHX, investors, NASDAQ, NASDAQ:GEDU, NASDAQ:INHX, NASDAQ:VRUS, Pearson, Pharmasset, premium, publishing group, report, sector, shares, takeover, trading, VRUS | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.